NDASUBCUTANEOUSEMULSION
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
CAMCEVI KIT (leuprolide) by Accord Biopharma is leuprolide, a gnrh agonist, acts as an inhibitor of gonadotropin secretion. Approved for prostate cancer, central precocious puberty, endometriosis. First approved in 2021.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAMCEVI KIT is a subcutaneous emulsion formulation of leuprolide, a GnRH agonist approved in May 2021 by Accord Biopharma. It suppresses gonadotropin and steroid secretion through chronic GnRH pathway inhibition, with effects reversible upon discontinuation. The drug treats prostate cancer, endometriosis, central precocious puberty, and has off-label use across 20+ additional indications including breast cancer, lymphomas, and transgender health.
Peak12.7 years to LOE
The product is in peak commercial phase with 12.7 years of patent protection remaining, indicating sustained revenue potential and stable team sizing through mid-2030s.
Mechanism of Action
Leuprolide, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon…
Indications (3)
Worked on CAMCEVI KIT at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.